All In Biotech

Drug Trial Radar · NCT04480502

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingTitle says "pivotal". Randomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

207

Actual

Start

Dec 9, 2020

Primary completion

Oct 2024

Study completion Oct 2024

Sponsor

Lead sponsor
Tracon Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.

Conditions

  • Undifferentiated Pleomorphic Sarcoma
  • Myxofibrosarcoma

Interventions

  • EnvafolimabBiological

    PD-L1 single domain antibody for subcutaneous injection.

  • IpilimumabDrug

    CTLA-4 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) by RECIST 1.1 assessed by blinded independent central reviewTime frame: 40 months

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • University of California, Los Angeles

    Los Angeles, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Stanford University

    Stanford, California

  • University of Colorado

    Aurora, Colorado

  • Mayo Clinic, Jacksonville

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Evanston, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University in St. Louis

    St Louis, Missouri

  • Columbia University

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • University Hospitals

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University (Sidney Kimmel Cancer Center)

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical College of Wisconsin

    Wauwatosa, Wisconsin

  • Royal Marsden

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.